Browse

Therapeutic evaluation of sustained-releasing praziquantel (SRP) for clonorchiasis: phase 1 and 2 clinical studies

DC Field Value Language
dc.contributor.authorChoi, M. H.-
dc.contributor.authorChang, B. C.-
dc.contributor.authorLee, S. J.-
dc.contributor.authorJang, I. J.-
dc.contributor.authorShin, S. G.-
dc.contributor.authorKho, W. G.-
dc.contributor.authorChun, J. H.-
dc.contributor.authorHong, S. T.-
dc.date.accessioned2010-01-06-
dc.date.available2010-01-06-
dc.date.issued2006-12-16-
dc.identifier.citationKorean J Parasitol. 2006 Dec;44(4):361-6.en
dc.identifier.issn0023-4001 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17170578-
dc.identifier.urihttps://hdl.handle.net/10371/25667-
dc.description.abstractSustained-releasing praziquantel (SRP) tablet was designed for single dose treatment regimen of clonorchiasis. A previous pre-clinical study confirmed its sustained-releasing characteristics and a better cure rate than conventional praziquantel (PZQ). In this clinical study, the pharmacokinetics of this SRP tablet were investigated in human volunteers (phase 1; 12 volunteers), and its curative efficacy was examined in clonorchiasis patients (phase 2; 20 volunteers). In the phase 1 clinical study, blood concentrations of both tablets showed wide individual variation. The AUClast of SRP was 497.9 +/- 519.0 ng * hr/ml (mean +/- SD) and PZQ of 628.6 +/- 695.5 ng * hr/ml, and the AUCinf of SRP was 776.0 +/- 538.5 ng * hr/ml and of PZQ 658.6 +/- 709.9 ng * hr/ml. Cmax values of SRP and PZQ were 90.7 +/- 82.2 ng/ml and 214.9 +/- 251.9 ng/ml, and Tmax values were 3.42 +/- 1.43 hr and 1.96 +/- 1.23 hr, respectively. SRP tablets showed similar AUC values, but lower Cmax and longer Tmax values than PZQ. In the phase 2 study, SRP at 30 mg/kg (single dose) achieved a 60% cure rate and a 95.5% egg reduction rate. The cure rate of a single dose SRP was unsatisfactory compared with that of the conventional PZQ dose, but much better than that achieved by a single dose PZQ.en
dc.language.isoenen
dc.publisherKorean Society of Parasitology / The Korean Society for Parasitologyen
dc.subjectAdulten
dc.subjectAnimalsen
dc.subject*Anthelmintics/adverse effects/pharmacokinetics/therapeutic useen
dc.subjectArea Under Curveen
dc.subjectClonorchiasis/*drug therapyen
dc.subjectClonorchis sinensis/*drug effects/isolation & purificationen
dc.subject*Delayed-Action Preparations/pharmacokinetics/therapeutic useen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectParasite Egg Counten
dc.subject*Praziquantel/adverse effects/pharmacokinetics/therapeutic useen
dc.titleTherapeutic evaluation of sustained-releasing praziquantel (SRP) for clonorchiasis: phase 1 and 2 clinical studiesen
dc.typeArticleen
dc.contributor.AlternativeAuthor최민호-
dc.contributor.AlternativeAuthor장병찬-
dc.contributor.AlternativeAuthor이성진-
dc.contributor.AlternativeAuthor장인진-
dc.contributor.AlternativeAuthor신상구-
dc.contributor.AlternativeAuthor고원규-
dc.contributor.AlternativeAuthor천진호-
dc.contributor.AlternativeAuthor홍성태-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pharmacology (약리학전공)Journal Papers (저널논문_약리학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse